Moderna (NASDAQ:MRNA) Given Sector Perform Rating at Royal Bank of Canada

Moderna (NASDAQ:MRNA)‘s stock had its “sector perform” rating reaffirmed by equities research analysts at Royal Bank of Canada in a report released on Tuesday,Benzinga reports. They currently have a $40.00 price objective on the stock. Royal Bank of Canada’s target price suggests a potential upside of 11.97% from the stock’s previous close.

A number of other analysts have also recently weighed in on MRNA. Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research note on Tuesday, November 26th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Evercore ISI reduced their price objective on Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research note on Monday, January 27th. Finally, UBS Group lowered their target price on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $61.58.

Moderna Stock Performance

NASDAQ MRNA traded up $2.73 on Tuesday, reaching $35.72. The stock had a trading volume of 15,358,387 shares, compared to its average volume of 12,916,324. The stock has a market cap of $13.75 billion, a P/E ratio of -6.14 and a beta of 1.59. Moderna has a 12-month low of $29.25 and a 12-month high of $170.47. The business’s 50-day moving average price is $38.61 and its 200 day moving average price is $53.82. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 2,664 shares of company stock worth $115,210 in the last quarter. Company insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Large investors have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its holdings in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its stake in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna in the 4th quarter valued at about $37,000. Finally, Larson Financial Group LLC raised its stake in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.